Coya Therapeutics secures FDA fast track status for COYA 302

Learn more Coya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for COYA 302, ...
PlanetF1

F1 Fast Track: Gabriele Mini delivers; F2 Miami Sprint steals the show

Gabriele Mini delivered in Miami, where Formula 2 rocked up and uncorked a Sprint race spectacle for the ages.

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinoma…

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Cure Today

FDA Gives Fast Track Designation to Stenoparib in Advanced Ovarian Cancer

Stenoparib, targeting PARP1/2 and tankyrase 1/2, offers a unique mechanism for treating advanced ovarian cancer. The FDA's fast track designation facilitates expedited development and review, with ...
Healio

FDA grants fast-track designation to myotonic dystrophy type 1 treatment

Please provide your email address to receive an email when new articles are posted on . The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals ...
Seeking Alpha

Greenwich LifeSciences: Fast Track Designation Does Not Solve Fundamental Issues

Greenwich LifeSciences focuses on developing GLSI-100, a HER2-positive breast cancer vaccine, recently granted FDA Fast Track designation. GLSI's Fast Track status offers regulatory advantages but ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug ...
Morningstar

A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster A2 Biotherapeutics, Inc. (A2 Bio), a ...